Who we are
“Innofamily since 70’s”
The Paolo Gobbi Frattini company
Paolo Gobbi Frattini srl was founded in the 1970s on the groundwork of the family business where Renzo Gobbi Frattini (father), a pioneer in the automated production of flexible bags and infusion sets, was the creator of major technological innovations with important patents on products and production processes that are still very relevant today.
Over the years, Paolo Gobbi Frattini through the company bearing the same name, has founded several other companies as the only partner, including Haemopharm, maintaining the innovative tradition in the biomedical sector with innovative in-house manufactured process machines and multiple product patents in drug management through biomedical bags and their accessories.
The production
The Paolo Gobbi Frattini Group produces flexible bags for sterile solutions in PVC and PVC-FREE, drug reconstitution and delivery systems, and components for advanced therapeutic applications. The raw materials used are selected with the highest professionalism with strict criteria of biocompatibility with molecules and adequate oxygen and vapor barrier. The company is distinguished by its level of specialization, an ongoing commitment to research and development of innovative solutions, with a focus on the design of advanced systems and components for drug reconstitution and delivery, many of which are patented. Paolo Gobbi Frattini Group srl’s advanced bag systems and their accessories are developed and produced entirely in-house, in the Lombardy plant in Tovo S. Agatha (SO), in compliance with the strictest and highest quality standards.
Proprietary technology of production lines
An important competitive advantage is the exclusive and proprietary technology of its production lines, which has been a hallmark of the company since its beginnings. Modular business management ensures maximum efficiency through versatile, advanced processes, high product reliability and consistent performance levels over time.
Direct involvement of ownership in the management of the company
Paolo Gobbi Frattini owns 100 percent of the share capital of all group companies and is personally present and operational as CEO of the companies, guaranteeing a long-term perspective. This is a key aspect of corporate identity, facilitating communication, accelerating decision-making processes, to better meet the needs of Clients.
Linee guida strategiche
Our mission & vision
Haemopharm’s mission is to consolidate its leadership, both technologically and in the development of numerous patents, by pursuing sustainable growth as a partner of choice for large companies globally. The strategy of international expansion is part of a broader logic of growth, based on a dynamic and modern organisation, able to compete globally, and to be first in very specialised market areas, with high quality products and services.
A dynamic entrepreneurial spirit, geared toward a constant pursuit of excellence for more than 30 years of history, places at the center of the Company’s strategy three fundamental strategic assets that represent the pillars of the Paolo Gobbi Frattini srl Vision:
Innovation
- OF PROCESSES, thanks to the proprietary technology of the machines, to the modular and versatile management of production;
- OF PRODUCTS, because the company develops solutions with advanced functional features, with high added value;
- OF COMPETENCES, because Haemopharm professionals have high-level specialist skills, always working with a cutting-edge design approach.
Diversification
- Because Haemopharm solutions meet the needs of various therapeutic areas, such as pharmaceutical compounding, drug reconstitution, dialysis, nutrition, cryopreservation of cells and tissues, ozone therapy and ophthalmology.
Synergies
Because thanks to a consolidated network of partnerships and collaborations, Haemopharm is able to activate strategic collaborations along the supply chain, and to manage every phase of the project with the highest quality and efficiency, and in a short time.
A worldwide commercial network
The ability to preside over the global market is a crucially important aspect of company policy. Clients, in fact, are increasingly sensitive to establishing collaborations with industry players who, in addition to offering products of excellence, are also able to guarantee a widespread presence in the different areas of the world, thanks to the support of strategic partnerships.
Pursuing these objectives, the Paolo Gobbi Frattini Group has developed over the years commercial agreements in Europe, North and South America, Australia, the Middle East and the Far East, thanks to which it is able to actively preside over the geographical areas of greatest interest for its business.
Direct presence in Serbia, through Quatalia Science d.o.o.
With headquarters in Belgrade, Quatalia Science d.o.o is a company controlled by Haemopharm which has been established to consolidate local business and to facilitate the emerging markets penetration. Quatalia also deals with the recording of numerous Marketing Authorizations, especially for oncological treatment, antibiotics and medical devices.
Competence and constant updates on Regulatory Affairs
Both the companies – Haemopharm and Quatalia – have their own Regulatory Affairs departments, in charge of supervising the Marketing Authorization procedures, through dossiers preparation for drugs, and technical files for the CE-marked medical devices.
FDA Certifications
The acquisition of FDA Certifications, necessary for the commercialization of medical devices in the USA, represents, moreover, an important step in Haemopharm’s development strategy.
Partnership
ADVATIS: Joint-venture with Medigas Italia
A network of partnerships and business relationships, on a national and international scale, allows Paolo Gobbi Frattini srl to extend its core business and diversify its offer through collaboration with important players in the sector.
In May 2005, Haemopharm signed a cooperation agreement with SIAD Healthcare for the development, production and marketing of a new line of bags for cryopreservation of stem cells and tissues: SAFE2.
The agreement with Medigas Italia expands Haemopharm’s presence in a new market segment and allows it to be joined by a trusted Partner to continue the search for increasingly innovative solutions for cell therapies. The goal for both companies is to offer a product line that fully meets the rigorous needs of cryopreservation banks.
The ongoing collaboration with Medigas Italia materialized in 2015 in a contractual joint venture: ADVATIS, “Advanced Therapies Innovative Solutions,” was born, providing innovative solutions in the field of cryopreservation and cell therapies and offering a wide range of products to cover the different stages of stem cell and tissue collection, handling and storage. With a high level of flexibility and with the support of the R&D team, ADVATIS can offer tailor-made solutions to meet any customer need.
From industrial research to treatment
Sant’Agatha Medical Center
Haemopharm is a unique entrepreneurial structure, due to its clinical division, the St. Agatha Medical Center, which faithfully represents the company’s DNA and its natural tendency to a tight collaboration with the medical-scientific world.
Corporate Responsibility
The success of Paolo Gobbi Frattini srl is based on a solid network of values, to which the Company’s team renews its commitment on a daily basis.
Responsibility, work ethics, reliability, respect for the individual, transparency in the running of the Company, fairness in the management of human resources, fairness and clarity in contracts, loyalty to commitments made, observance of laws, respect for institutions in every country in the world: these are the fundamental reference principles, which are combined with a culture oriented towards the Client, with whom Paolo Gobbi Frattini srl aims to establish solid and lasting partnerships.
The responsibility of Paolo Gobbi Frattini srl is also expressed towards the environment, with the search for technical solutions that allow a better use of resources and greater environmental sustainability, waste materials are supplied to companies specializing in recycling while most of the energy is produced through its own photovoltaic plant.